Advanced glycation end products in diabetic complications

Michael Brownlee

Research output: Contribution to journalArticle

34 Scopus citations

Abstract

Advanced glycation end products accumulate as a function of the level of chronic hyperglycemia via generation of reactive dicarbonyl intermediates. Inside cells, advanced glycation end products accumulate rapidly and cause altered function of intracellular proteins. Outside cells, advanced glycation end products accumulate over longer periods of time, interfering with normal extracellular matrix interactions and causing advanced glycation end product receptor-mediated pathologic changes in gene expression. In animal models, pharmacologic inhibition of advanced glycation end product formation prevents diabetic complications in the retina, glomerulus, peripheral nerve, and artery. Efficacy results from a study in type I diabetic patients with overt nephropathy are anticipated in the third quarter of 1998.

Original languageEnglish (US)
Pages (from-to)291-297
Number of pages7
JournalCurrent Opinion in Endocrinology and Diabetes
Volume3
Issue number4
DOIs
StatePublished - Jan 1 1996

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Advanced glycation end products in diabetic complications'. Together they form a unique fingerprint.

  • Cite this